Product Information
BIDIL 20 MG-37.5 MG TABLET is a brand product labeled by Azurity Pharmaceuticals Inc., priced at $4.3452 per EA under NDC 24338001009. Its NADAC has been published 278 times since Nov 11, 2020.
FDA first approved this application on Jun 23, 2005. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
37.5; 20 mg/1; mg/1
Manufacturer
Azurity Pharmaceuticals Inc.NDC
24338001009
Classification
Brand
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
2/18/2026
Active Ingredients
HYDRALAZINE HYDROCHLORIDE; ISOSORBIDE DINITRATEApproval Type
New Drug (NDA)
FDA Application
NDA020727FDA Approved
6/23/2005
TE Code
AB
On Market Since
12/5/2012
Pharmacological Classes
Price Statistics
The NADAC for BIDIL 20 MG-37.5 MG TABLET has been published 278 times since Nov 11, 2020, and over the history we have for it it has risen 21.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $4.3452 per EA |
|---|---|
| All-time high | $4.4016 (Sep 11, 2024) |
| All-time low | $3.5578 (Dec 23, 2020) |
| 52-week high | $4.3475 |
| 52-week low | $4.3452 |
| Median price | $4.1927 |
| Average price | $4.1018 |
| Largest weekly change | +10.0% (Oct 12, 2022) |
| Weeks tracked | 278 |
| Tracking since | Nov 11, 2020 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Hydralazine hydrochloride and Isosorbide dinitrate market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Azurity Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Hydralazine hydrochloride and Isosorbide dinitrate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Arteriolar Vasodilator class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of BIDIL 20 MG-37.5 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for BIDIL 20 MG-37.5 MG TABLET, manufactured by Azurity Pharmaceuticals Inc., is $4.3452 per EA (NDC 24338001009), effective Sep 30, 2026.
How has the price of BIDIL 20 MG-37.5 MG TABLET changed over time?
Over the history we have for it, the NADAC for BIDIL 20 MG-37.5 MG TABLET has risen 21.3%. It has been tracked across 278 weekly CMS publications since Nov 11, 2020.
What are the highest and lowest recorded NADAC prices for BIDIL 20 MG-37.5 MG TABLET?
Since Nov 11, 2020, the NADAC for BIDIL 20 MG-37.5 MG TABLET has ranged from a low of $3.5578 (Dec 23, 2020) to a high of $4.4016 (Sep 11, 2024), with a median of $4.1927 per EA.
Are there cheaper alternatives to BIDIL 20 MG-37.5 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of BIDIL 20 MG-37.5 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures BIDIL 20 MG-37.5 MG TABLET?
BIDIL 20 MG-37.5 MG TABLET (NDC 24338001009) is labeled by Azurity Pharmaceuticals Inc., and CMS classifies it as a brand product.